Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of KD-380 in CIDP and MMN
jRCT2051240028Phase 3Active, not recruiting
- Sponsor
- KM Biologics
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of KD-380 in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) (4 arms), sponsored by KM Biologics. Started Jun 2024; status: active, not recruiting.
02
Drugs
KD-380
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on jRCT2051240028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240028.